[Pharmacological modulation of NO synthesis in patients with arterial hypertension and endothelial dysfunction]. / Farmakologicheskaia moduliatsiia sinteza NO u bol'nykh s arterial'noi gipertoniei i éndotelial'noi disfunktsiei.

An open, comparative, cross-over 8-week trial of beta-blockers nebivolol and metoprolol in 30 patients with arterial hypertension (AH) studied the office, ambulatory blood pressure and heart rate levels, endothelium-dependent vasorelaxation, endothelial NOS and NO production. It was found that nebivolol activated the system eNOS-NO and improved vasomotor parameters of the endothelium. Metoprolol failed to activate enzyme eNOS activity and NO production to the same level and did not improve the endothelial vasomotor function. The antihypertensive activity of nebivolol was higher than that of metoprolol. Thus, nebivolol can be used in patients with AH and cardiovascular risk factors to correct endothelial dysfunction.

[Clinical and metabolic effects of cardioselective beta-adrenoblockers nebivolol and metoprolol in patients with hypertension and ischemic heart disease associated with type 2 diabetes]. / Klinicheskie i metabolicheskie éffekty kardioselektivnykh beta-adrenoblokatorov nebivolola i metoprolola u bol'nykh arterial'noi gipertoniei i ishemicheskoi bolezn'iu serdtsa v sochetanii s sakharnym diabetom 2-go tipa.

AIM: To compare efficacy and safety of cardioselective beta-adrenoblockers nebivolol and metoprolol in patients with hypertension and ischemic heart disease (IHD) combined with type 2 diabetes. MATERIAL AND METHODS: Patients with IHD, class II-III angina and moderately severe compensated or subcompensated type II diabetes (n=35, 29 with grade 1-2 hypertension according to WHO 1999 classification) were divided into 2 groups with similar clinical and laboratory characteristics. Patients of group 1 received metoprolol (50-100 mg/day), of group 2--nebivolol (5-7.5 mg/day) for 8 weeks. Data of physical investigation, exercise tests, 24-hour blood pressure and heart rate monitoring, analysis of lipid spectrum and glycemic profile were used for assessment of treatment efficacy. RESULTS: Decrease of number of anginal attacks and nitroglycerine requirement was more pronounced in nebivolol treated patients. The use of both drugs was associated with lowering of blood pressure and heart rate. There were no unfavorable changes of parameters of carbohydrate and lipid metabolism. Pronounced (by 19.2%) lowering of triglycerides was observed in nebivolol treated patients. Both drugs were well tolerated. CONCLUSION: Nebivolol and metoprolol are effective and safe antianginal agents in patients with IHD and hypertension combined with type 2 diabetes. However in doses used nebivolol produced more favorable metabolic and hemodynamic effects.

[Effect of dipyridamole on blood levels of fibroblast growth factor and vascular endothelial growth factor in patients with ischemic heart disease]. / Vliianie dipiridamola na soderzhanie v krovi sosudistogo éndotelial'nogo faktora rosta i faktora rosta fibroblastov u bol'nykh ishemicheskoi bolezn'iu serdtsa.

Addition if dipyridamole to standard therapy in patients with ischemic heart disease was associated with improvement of functional class of angina and elevation of blood levels of fibroblast growth factor and Vascular Endothelial Growth Factor.

[Experience of the use of nebivolol in the treatment of hypertension in postmenopausal women]. / Prakticheskii opyt uspeshnogo primeneniia nebivolola pri lechenii arterial'noi gipertonii u zhenshchin v postmenopauze.

Nebivolol was given to 30 hypertensive postmenopausal women as monotherapy (5-10 mg/day) or in combination with hydrochlorothiazide. Clinical effect was achieved in 76.6 and 86.7% of women on mono- and combination therapy, respectively. Hypotensive effect was confirmed by 24-hour blood pressure monitoring. Blood pressure lowering was associated with decrease of total peripheral resistance and regression of left ventricular hypertrophy. Nebivolol appeared to be metabolically neutral and only sporadic adverse effects were registered.

[Effects of nebivolol on microcirculation, platelet aggregation and blood viscosity in patients with essential hypertension]. / Vliianie nebivolola na mikrotsirkuliatsiiu, agregatsiiu trombotsitov i reologiiu krovi u bol'nykh arterial'noi gipertoniei.

AIM: To assess effects of a selective beta1-adrenoreceptor blocker acting in part via nitric oxide nebivolol on microcirculation, platelet aggregation and blood viscosity. MATERIAL: Thirty patients with mild-to-moderate essential hypertension (mean age 54,1-/+9,3 years). METHODS: Ambulatory blood pressure monitoring, laser doppler flowmetry, registration of spontaneous and ADP-induced platelet aggregation. Nebivolol (5 mg/day) or its combination with hydrochlorothiazide (12,5 mg/day) were given for 3 months. RESULTS: Treatment with nebivolol caused significant reduction of systolic and diastolic blood pressures. Spontaneous and low dose ADP-induced platelet aggregation significantly decreased during treatment while blood viscosity did not change. In patients with hyperemic and spastic-hyperemic hemodynamic type of microcirculation improvement of microcirculation occurred due to changes of myogenic tone of arterioles and precapillary sphincters and 'damping' properties of resistance arterioles. CONCLUSION: In patients with essential hypertension hypotensive action of nebivolol was associated with antiaggregation effect and improvement of blood flow in microvascular networks.

[Assessment of efficacy and safety of nebivolol in patients with stable effort angina]. / Otsenka éffektivnosti i bezopasnosti primeneniia b-adrenoblokatora tret'ego pokoleniia nebivolola u bol'nykh so stabil'noi stenokardiei napriazheniia.

AIM: To study efficacy and safety of nebivolol in patients with stable angina pectoris. MATERIAL: Twenty patients with stable effort angina pectoris and positive exercise test without contraindications to beta-blockers, signs of NYHA class III-IV heart failure, and obstructive lung disease. After 5-7 days of control period all patients were given nebivolol (starting dose 5 mg/day) for 8 weeks. Graded exercise tests on treadmill and patient's diaries were used for assessment of treatment efficacy. RESULTS: Treatment with nebivolol (5-10 mg o.d. ) was associated with significant slowing of heart rate, lowering of blood pressure, and increase of exercise duration until appearance of angina or 1 mm ST-segment depression. Nebivolol did not affect left ventricular ejection fraction, bronchial conductance, or results of biochemical tests (including lipid profile). Adverse reaction (dizziness which disappeared after lowering of a dose) was registered in 1 patient. CONCLUSION: Nebivolol is an effective drug for the treatment of patients with stable angina.

[Cardiological use of mononitrates]. / Ispol'zovanie monotitratov v kardiologii.

The study has provided strong evidence for the marked antihypertensive and antiischemic effects of isosorbide-5-mononitrate (I-5-M)--the drug Monochinque retard, 50 mg (A Monarini Group, Berlin Chemie). It contributed to the reduction of the number of anginal attacks and to the alleviation of myocardial ischemia, as evidenced by Holter monitoring. The findings also indicate that there are positive changes in central hemodynamic parameters, such as left ventricular systolic and diastolic functions when Monochinque was given. The data presented suggest that Monochinque, 50 mg, an I-5-M has a positive effect on the clinical manifestations of pain and painless forms of coronary heart disease and that it alleviated functional classes II-IV heart failure.